Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Targeting BRD9 in KMT2A-rearranged Acute Myeloid Leukemia to circumvent MEN1 inhibitor resistance

Jenny Hsiao-Wen Huang, Eve Ioannou, Tommaso de Marchi, Marije Havermans, Claudia Erpelinck-Verschueren, Daniela Wenge, Scott Armstrong, Ruud Delwel, Ning Qing Liu

Blood (2025) 146 (Supplement 1): 1463.

https://doi.org/10.1182/blood-2025-1463

Published: 2025

Journal Articles

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

Jing Liu, Xuefei Sun, Qu Cui, Yuchen Wu, Yuedan Chen, Ruixian Xing, Wenyuan Lai, Xueyan Bai, Jun Qian, Qing Liu, Huixiu Han, Lin Fu, Yuanbo Liu

Blood (2025) 146 (Supplement 1): 5418.

https://doi.org/10.1182/blood-2025-5418

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Elizabeth Budde, Marissa Del Real, John Baird, Lu Chen, Joo Song, Xiuli Wang, Swetha Thiruvengadam, Marie Hu, Alan Macias, Emanuela Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Stephen Forman, Larry Kwak

Blood (2025) 146 (Supplement 1): 268.

https://doi.org/10.1182/blood-2025-268

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Ibrahim Aldoss, Xiuli Wang, Lu Chen, Joo Song, Karamjeet Sandhu, Alan Macias, Neguine Sanani, Baishakhi Barva, Min Guan, Ruby Espinosa, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Guido Marcucci, Elizabeth Budde, Larry Kwak, Stephen Forman

Blood (2025) 146 (Supplement 1): 813.

https://doi.org/10.1182/blood-2025-813

Published: 2025

Journal Articles

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study

Yuedan Chen, Qu Cui, Jun Qian, Wenyuan Lai, Xueyan Bai, Jing Liu, Ruixian Xing, Huixiu Han, Qing Liu, Yuchen Wu, Yuanbo Liu, Xuefei Sun, Lin Fu

Blood (2025) 146 (Supplement 1): 3694.

https://doi.org/10.1182/blood-2025-3694

Published: 2025

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

Naturally Occurring Mutations in Human T Cell Lymphomas Enhance Engineered T Cell Therapies

Julie Garcia, Jay Daniels, Yujin Lee, Iowis Zhu, Kathleen Cheng, Qing Liu, Daniel Goodman, Cassandra Burnett, Calvin Law, Chloe Thienpoint, Josef Alavi, Camillia Azimi, Garrett Montgomery, Kole Roybal, Jaehyuk Choi

Blood (2023) 142 (Supplement 1): 884.

https://doi.org/10.1182/blood-2023-180895

Published: 2023

Journal Articles

The Novel Biomarkers for Predicting Prognosis and Recurrence in Primary Central Nervous System Lymphoma: Exosomal Protein and Exosomal microRNA

Liwei Lv, Xuefei Sun, Yuchen Wu, Huanguang Liu, Wenyuan Lai, Qu Cui, Yuedan Chen, Qing Liu, Ruixian Xing, Xueyan Bai, Jun Qian, Jingjing Lu, Shengjun Sun, Fangang Meng, Nan Ji, Yuanbo Liu

Blood (2023) 142 (Supplement 1): 6123.

https://doi.org/10.1182/blood-2023-184544

Published: 2023

Journal Articles

Prime Editing of the α-Thalassemia Hb Constant Spring Mutation

Congwen Shao, Qing Liu, Jinchao Xu, Ye Xin, Jianxiang Zhang, Yuhua Ye, Hualei Luo, Xinhua Zhang, Xiangmin Xu, Peng Xu

Blood (2023) 142 (Supplement 1): 5001.

https://doi.org/10.1182/blood-2023-185425

Published: 2023

Journal Articles

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Chunxiao Zhang, Garret MK Leung, MBBS, Sze Pui Tsui, MSc, Ho-Wan Ip, MBBS,FRCPA, Edmond S. K. Ma, MD, Chun Hang Au, PhD, Chris T.L. Chan, PhD, Ka Lam Nelson Ng, PhD, Sze Fai Yip, MD, Bonnie Kho, MD, Harold K K Lee, MD, Qing LIU, Thomas Wing Yan Leung, Yok Lam Kwong, MD FRCP, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 3825.

https://doi.org/10.1182/blood-2019-126510

Published: 2019

Journal Articles

A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells

Carlos Caicedo-Carvajal, Ph.D, Qing Liu, Ph.D, Andre Goy, MD, Andrew L Pecora, MD, Anthony R Mato, MD, Tatyana Feldman, MD, K. Stephen Suh, Ph.D

Blood (2010) 116 (21): 426.

https://doi.org/10.1182/blood.V116.21.426.426

Published: 2010

Journal Articles

Inactivation of INK4a/ARF Accelerates the Development of PTEN Deficient T-ALL

Yaling Yang, PhD, Xiuhua Gao, MD, PhD, Xin Han, MD, MS, Xiaoyan Huang, MD., MS, Qing Liu, MS, Yu H. Zhang, MD, C. Cameron Yin, MD, PhD, Ling Chen, M. James You, MD, PhD

Blood (2010) 116 (21): 4197.

https://doi.org/10.1182/blood.V116.21.4197.4197

Published: 2010

Journal Articles

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Blood (2010) 115 (13): 2619–2629.

https://doi.org/10.1182/blood-2009-09-242438

Published: 2010

Includes: Supplemental data

Journal Articles

Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss

Hind Medyouf, Xiuhua Gao, Florence Armstrong, Samuel Gusscott, Qing Liu, Amanda Larson Gedman, Larry H. Matherly, Kirk R. Schultz, Francoise Pflumio, Mingjian James You, Andrew P. Weng

Blood (2010) 115 (6): 1175–1184.

https://doi.org/10.1182/blood-2009-04-214718

Published: 2010

Includes: Supplemental data

Journal Articles

Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.

Hind Medyouf, Xiuhua Gao, Florence Armstrong, Samuel Gusscott, Qing Liu, BS, Amanda Larson Gedman, Larry Matherly, PhD, Kirk R. Schultz, MD, Francoise Pflumio, PhD, M. James You, MD, PhD, Andrew P. Weng, MD, PhD

Blood (2009) 114 (22): 8.

https://doi.org/10.1182/blood.V114.22.8.8

Published: 2009

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Blood (2008) 112 (13): 5180–5189.

https://doi.org/10.1182/blood-2008-01-133108

Published: 2008

Journal Articles

Resveratrol Inhibits Proliferation and Induces Apoptosis of Mouse Pten Null T-Cell Acute Lymphocytic Leukemia Cells

Qing Liu, Xiuhua Gao, Cheng C. Yin, Chen Ling, M. James You

Blood (2008) 112 (11): 3967.

https://doi.org/10.1182/blood.V112.11.3967.3967

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting BRD9 in KMT2A-rearranged Acute Myeloid Leukemia to circumvent MEN1 inhibitor resistance

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Naturally Occurring Mutations in Human T Cell Lymphomas Enhance Engineered T Cell Therapies

The Novel Biomarkers for Predicting Prognosis and Recurrence in Primary Central Nervous System Lymphoma: Exosomal Protein and Exosomal microRNA

Prime Editing of the α-Thalassemia Hb Constant Spring Mutation

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells

Inactivation of INK4a/ARF Accelerates the Development of PTEN Deficient T-ALL

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss

Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Resveratrol Inhibits Proliferation and Induces Apoptosis of Mouse Pten Null T-Cell Acute Lymphocytic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only